FGF17 and acute myeloid leukemia: Furthermore, FGF10/FGF17 has been identified as a prognostic and drug response marker in acute myeloid leukemia [162], suggesting that small-molecule inhibitors of FGF10 and FGF17 are promising therapeutic targets.